Dr Lim Yi Wan
Senior Consultant, Department of Haematology Oncology, National University Cancer Institute, Singapore (NCIS)
Dr Lim Yi Wan obtained her medical degree from the University of Cambridge, England. She received her postgraduate qualification (MRCP) from the Royal College of Physicians UK and completed her advanced specialty training in Medical Oncology at the National University Hospital (NUH). Dr Lim currently practices as senior consultant medical oncologist in the Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS) and NUH. Her main area of interest includes gynaecological and breast oncology.
Education and Fellowships
MBBS, MRCP (UK)
- Breast Cancer
- Gynaecological Cancer
Awards and Honours
- EXSA Silver Award 2007
- EXSA Silver Award 2009
- Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemo-naive breast cancer patients Annals of Oncology, April 2010.
- Poster presentation in ASCO (American Society of Clinical Oncology) 2009 meeting: Inter-ethnic differences in CYP3A4 inhibition by ketoconazole on docetaxel pharmacokinetics (PK) and pharmacodynamics (PD).
- Post-treatment tumour gene expression signatures are more predictive of treatment outcomes than baseline signatures in breast cancer. Pharmacogenetics & Genomics 19(11):833-842, November 2009.
- Chemotherapy-induced tumour gene expression changes in human breast cancers. Pharmacogenetics & Genomics 19(3):181-192, March 2009.
- PXR, CAR and HNF4α genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients. The Pharmacogenomics Journal 2008 (8), 139-146.
Updated as of 9 November 2016